ArticleNature communications2022
Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Differential COVID-19 infection rates in children, adults, and elderly: Systematic review and meta-analysis of 38 pre-vaccination national seroprevalence studies.Journal of global health · 2023Pooled it
- Age-stratified infection fatality rate of COVID-19 in the non-elderly population.Environmental research · 2023Pooled it
- Impact of the COVID-19 Pandemic on Coronary Heart Disease Admissions and Mortality in Mexico: An Ecological Study.Health science reports · 2026Article
- Potential value streams of an integrated Canadian serosurveillance network.Canadian journal of public health = Revue canadienne de sante publique · 2026Article
- Impact of the SARS-CoV-2 pandemic on healthy aging and functionality in older Mexican adults: insights from the MHAS cohort.Aging clinical and experimental research · 2026Article
- A population-based case-control study of COVID-19: methodological considerations on the role of testing bias.Journal of public health (Oxford, England) · 2025Article
- Titers of IgG, IgM, and IgA Against SARS-CoV-2 in Healthcare Workers from a General Hospital in Mexico City.Diseases (Basel, Switzerland) · 2025Article
- SARS-CoV-2 seroprevalence and COVID-19 vaccination coverage in two states of Nigeria from a population based household survey.Scientific reports · 2025Article
- Challenges and Approaches to Establishing Multi-Pathogen Serosurveillance: Findings from the 2023 Serosurveillance Summit.The American journal of tropical medicine and hygiene · 2024Article
- A panoramic view of hospitalized young children in the metropolitan area of the valley of Mexico during COVID-19.IJID regions · 2023Article
- Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.Infection · 2023Article
- Comparing the evolutionary dynamics of predominant SARS-CoV-2 virus lineages co-circulating in Mexico.eLife · 2023Article
- Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.Pathogens and global health · 2023Article
- National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021SARS-CoV-2 antibody prevalence in school children.The Journal of infection · 2023Article
- Severe acute respiratory syndrome coronavirus 2 seroprevalence among patients with pulmonary tuberculosis.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies.European journal of internal medicine · 2023Review
- Comparative epidemiology of five waves of COVID-19 in Mexico, March 2020-August 2022.BMC infectious diseases · 2022Article
- Comparable diagnostic accuracy of SARS-CoV-2 Spike RBD and N-specific IgG tests to determine pre-vaccination nation-wide baseline seroprevalence in Mexico.Scientific reports · 2022Article
- Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.Vaccines · 2022Article
- Severe acute respiratory syndrome coronavirus 2 antibody prevalence in adult patients with short bowel syndrome-A German multicenter cross-sectional study.JPEN. Journal of parenteral and enteral nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Seroprevalence surveys provide estimates of the extent of SARS-CoV-2 infections in the population, regardless of disease severity and test availability. In Mexico in 2020, COVID-19 cases reached a maximum in July and December. We aimed to estimate the national and regional seroprevalence of SARS-CoV-2 antibodies across demographic and socioeconomic groups in Mexico after the first wave, from August to November 2020. We used nationally representative survey data including 9,640 blood samples. Seroprevalence was estimated by socioeconomic and demographic characteristics, adjusting by the sensitivity and specificity of the immunoassay test. The national seroprevalence of SARS-CoV-2 antibodies was 24.9% (95%CI 22.2, 26.7), being lower for adults 60 years and older. We found higher seroprevalence among urban and metropolitan areas, low socioeconomic status, low education and workers. Among seropositive people, 67.3% were asymptomatic. Social distancing, lockdown measures and vaccination programs need to consider that vulnerable groups are more exposed to the virus and unable to comply with lockdown measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.